Fibrosis News and Research RSS Feed - Fibrosis News and Research

Fibrosis is the growth of fibrous tissue.
Duchenne muscular dystrophy: direct effect on muscle stem cells? An interview with Dr Rudnicki

Duchenne muscular dystrophy: direct effect on muscle stem cells? An interview with Dr Rudnicki

For twenty years, it has been understood that dystrophin is expressed in differentiated muscle fibers where it is part of a protein complex that crosses the membrane and connects the extracellular matrix to the actin network inside the cell to provide structural integrity. [More]
Alternative splicing: a new approach to drug development? An interview with Lucy Donaldson

Alternative splicing: a new approach to drug development? An interview with Lucy Donaldson

RNA is becoming an interesting drug target as it takes possible intervention back one step to the synthesis of a target protein, instead of trying to block or inhibit a process. [More]
Three Case Western faculty members receive funding to develop new diagnostic technologies

Three Case Western faculty members receive funding to develop new diagnostic technologies

Three Case Western Reserve University faculty members have received funding to further develop emerging technologies aimed at malaria, cystic fibrosis, and sickle cell anemia. [More]
Insights into exosomes role in disease transmission gained using NanoSight from Malvern

Insights into exosomes role in disease transmission gained using NanoSight from Malvern

Data measured using the NanoSight NS300 from Malvern Instruments is providing new insights into the role of exosomes in diseases such as cancer, arthritis, Alzheimer’s disease and cystic fibrosis, in pioneering research at the University of Alabama - Birmingham (UAB). [More]
New breakthrough drug shows promise to fight antibiotic-resistant infections

New breakthrough drug shows promise to fight antibiotic-resistant infections

A New York pharmaceutical company, TGV-Laboratories, has developed a groundbreaking drug that shows promise in treating a wide variety of antibiotic-resistant fungal and bacterial infections. [More]
CosmosID announces $6M in Series B funding round

CosmosID announces $6M in Series B funding round

CosmosID, the leading genomic big data company focused on microbiome research, outbreak investigations, and infectious disease diagnostics, using next-generation DNA sequencing, announced $6M in Series B funding. [More]
Oral drug ivacaftor appears to be safe, beneficial to pre-school children with specific type of cystic fibrosis

Oral drug ivacaftor appears to be safe, beneficial to pre-school children with specific type of cystic fibrosis

The oral drug ivacaftor appears to be safe and could be beneficial to young children between the ages of 2 and 5 with a specific type of cystic fibrosis, according to new research published in The Lancet Respiratory Medicine journal. [More]
New study identifies DKK3 as a driver of kidney fibrosis

New study identifies DKK3 as a driver of kidney fibrosis

Chronic kidney disease can develop in response to a variety of insults and is characterized by progressive renal fibrosis and atrophy of kidney tubule. Therapeutic options are limited and the disease is often not detected until later stages. [More]
Fibrosis in kidney transplants driven by continuous injury

Fibrosis in kidney transplants driven by continuous injury

Clinically, kidney fibrosis can be used to assess stage, progression, and prognosis for both kidney transplants and kidney disease. There is debate as to whether kidney fibrosis is a maladaptive, injury-triggered process that inherently progresses to kidney failure or an adaptive wound-healing process that stabilizes the injury site. [More]
New machine-learning technique could be used to uncover previously unknown features of organisms

New machine-learning technique could be used to uncover previously unknown features of organisms

A powerful new machine-learning technique can be applied to large datasets in the biological sciences to uncover previously unknown features of organisms and their genes, according to a team led by researchers from the Perelman School of Medicine at the University of Pennsylvania. [More]
New Georgia Tech research center launched to manufacture living cells for cell-based therapies

New Georgia Tech research center launched to manufacture living cells for cell-based therapies

A $15.7 million grant from the Atlanta-based Marcus Foundation has helped launch a new Georgia Institute of Technology research center that will develop processes and techniques for ensuring the consistent, low-cost, large-scale manufacture of high-quality living cells used in cell-based therapies. [More]
New study shows bone marrow lesions could help identify rapidly progressing osteoarthritis

New study shows bone marrow lesions could help identify rapidly progressing osteoarthritis

A new study from the Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, shows lesions, which can best be seen on MRI scans, could help identify individuals who are more likely to suffer from more rapidly progressing osteoarthritis. [More]
MGH researchers find how metformin drug prevents progression of pancreatic cancer

MGH researchers find how metformin drug prevents progression of pancreatic cancer

Massachusetts General Hospital investigators may have uncovered a novel mechanism behind the ability of the diabetes drug metformin to inhibit the progression of pancreatic cancer. [More]
First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for diabetic eye disease, today announces that the first patient has been enrolled in its Phase II CIRCLE study evaluating the efficacy and safety of multiple doses of ocriplasmin in inducing total posterior vitreous detachment (PVD) in patients with non-proliferative diabetic retinopathy (NPDR). [More]
Pulmonary neuroendocrine cells act like sensor to orchestrate immune response

Pulmonary neuroendocrine cells act like sensor to orchestrate immune response

An uncommon and little-studied type of cell in the lungs has been found to act like a sensor, linking the pulmonary and central nervous systems to regulate immune response in reaction to environmental cues. [More]
New classification of coronary congenital diseases helps surgeons identify secondary defects

New classification of coronary congenital diseases helps surgeons identify secondary defects

A new classification of coronary congenital diseases is set to help surgeons identify secondary defects in the operating theatre. The scheme is outlined in a novel European Society of Cardiology position paper published today in Cardiovascular Research.1 Clinical cardiologists will also know what to look for on cardiovascular images. [More]
New class of sound wave could lead to revolution in stem cell therapy

New class of sound wave could lead to revolution in stem cell therapy

Acoustics experts have created a new class of sound wave - the first in more than half a century - in a breakthrough they hope could lead to a revolution in stem cell therapy. [More]
EORTC study examines DW-MRI in patients with resectable liver metastases from colorectal cancer

EORTC study examines DW-MRI in patients with resectable liver metastases from colorectal cancer

Diffusion weighted (DW) magnetic resonance imaging (MRI) is a widely used technique to detect and characterize cancers as well as to monitor response to therapy. DW-MRI offers numerous advantages for patients with cancer and their treating physicians. It is a non-invasive imaging tool which does not require the administration of contrast agents nor ionizing radiation. [More]
Antiscarring paste can halt fibrosis caused by radiation treatment

Antiscarring paste can halt fibrosis caused by radiation treatment

An antiscarring paste when applied to the skin of mice halts fibrosis caused by the radiation used in cancer therapy. That is according to a study led by researchers at Laura and Isaac Perlmutter Cancer Center to be published tomorrow in the January edition of the Journal of the Federation of American Societies for Experimental Biology, or FASEB. [More]
DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

DS Biopharma reports completion of DS102 Phase I trial for treatment of fatty liver disorders

DS Biopharma, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with an oral formulation of the active pharmaceutical ingredient DS102 (15-HEPE) which is being explored for the treatment of fatty liver disorders, such as non-alcoholic steatohepatitis (NASH) and pulmonary disorders, such as idiopathic pulmonary fibrosis (IPF). [More]
Advertisement
Advertisement